Here's a look at the top diet and exercise stories of 2023.Integrating a well-balanced diet and regular exercise into the lives of individuals facing a ...

The phase 3 RELATIVITY-123 trial was discontinued because it was unlikely for it to reach its goals.A phase 3 trial that evaluated treatment with Opdualag ...

Studies about menin inhibitors for patients with acute myeloid leukemia (AML) reflected many of this year’s advancements in the blood cancer space, which ...

Having never smoked, when she got the news she was stage 4 a year ago, everyone tried to support her and her husband, but we all knew her chances of beating ...

Molecular genotyping can improve lung cancer outcomes, recent research showed. A recent study showed that undergoing molecular genotyping before receiving ...

Undergoing treatment for a myeloproliferative neoplasm (MPN) can be extremely lonely, so it is beneficial to have a support system throughout the process, ...

The Food and Drug Administration (FDA) has accepted and granted priority review for the biologics license application for patritumab deruxtecan to treat ...

Tarlatamab showed promise in treating small-cell lung cancer. Tarlatamab, an immunotherapy drug, was shown to improve objective response rate (percentage of ...

It’s bad and probably helps cancer develop, it’s bad and probably makes symptoms worse and it’s bad and can lead to a lot of health issues (cancer and ...

The Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to SLS009, a CDK9 inhibitor, for the treatment of patients with ...

Years ago, when Dr. Shamim Salman started treating patients with myeloproliferative neoplasms (MPNs), she, unfortunately saw many patients die from the ...

Patients with EGFRexon 20 insertion-positive non-small cell lung cancer experienced antitumor activity after receiving Gilotrif plus Erbitux, according to ...